Intellia Therapeutics to Discuss Q2 2025 Earnings and Updates via Conference Call
ByAinvest
Thursday, Jul 31, 2025 7:32 am ET1min read
NTLA--
Intellia Therapeutics specializes in CRISPR-based therapies and has been focusing on developing novel, first-in-class medicines to address important unmet medical needs. The company's portfolio includes in vivo programs such as NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease [2].
In the last quarter, Intellia reported a revenue of $16.63 million, which exceeded expectations despite posting a loss of $1.10 earnings per share. The company's stock price surged 6.9% during mid-day trading on Friday, July 25, 2025, reaching a high of $13.66 and closing at $13.67. Analysts have issued various ratings and price targets for the stock, with a consensus rating of "Moderate Buy" and a target price of $33.37 [2].
The upcoming conference call is expected to provide investors with valuable information about Intellia's financial health and operational progress. Key topics to watch for include revenue growth, earnings per share, and any updates on the company's clinical trials and pipeline of gene-editing therapies.
References:
[1] https://www.stocktitan.net/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-ii7jswflkp01.html
[2] https://www.marketbeat.com/instant-alerts/intellia-therapeutics-nasdaqntla-trading-69-higher-time-to-buy-2025-07-25/
Intellia Therapeutics will hold a conference call on August 7, 2025, to discuss its second quarter 2025 financial results and operational highlights. The call will be available via a live webcast on the company's website and can be accessed by dialing 1-833-316-0545 (US) or 1-412-317-5726 (international). A replay will be available on the company's website starting at 12 p.m. ET on August 7, 2025.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company, has scheduled its second quarter 2025 earnings conference call for August 7, 2025, at 8:00 a.m. ET. The call will provide investors with insights into the company's financial performance and operational updates for the period. The conference call can be accessed by dialing 1-833-316-0545 (US) or 1-412-317-5726 (international). A live webcast will be available, and a replay will be accessible through Intellia's website starting at 12 p.m. ET on the same day [1].Intellia Therapeutics specializes in CRISPR-based therapies and has been focusing on developing novel, first-in-class medicines to address important unmet medical needs. The company's portfolio includes in vivo programs such as NTLA-2001 for transthyretin amyloidosis, NTLA-2002 for hereditary angioedema, and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease [2].
In the last quarter, Intellia reported a revenue of $16.63 million, which exceeded expectations despite posting a loss of $1.10 earnings per share. The company's stock price surged 6.9% during mid-day trading on Friday, July 25, 2025, reaching a high of $13.66 and closing at $13.67. Analysts have issued various ratings and price targets for the stock, with a consensus rating of "Moderate Buy" and a target price of $33.37 [2].
The upcoming conference call is expected to provide investors with valuable information about Intellia's financial health and operational progress. Key topics to watch for include revenue growth, earnings per share, and any updates on the company's clinical trials and pipeline of gene-editing therapies.
References:
[1] https://www.stocktitan.net/news/NTLA/intellia-therapeutics-to-hold-conference-call-to-discuss-second-ii7jswflkp01.html
[2] https://www.marketbeat.com/instant-alerts/intellia-therapeutics-nasdaqntla-trading-69-higher-time-to-buy-2025-07-25/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet